TAS-1553
- Generic Name
- TAS-1553
A Study of TAS1553 in Subjects With Relapsed or Refractory Acute Myeloid Leukemia (AML) and Other Myeloid Neoplasms
Phase 1
Terminated
- Conditions
- Acute Myeloid LeukemiaMyelodysplastic/Myeloproliferative NeoplasmMyeloproliferative Neoplasm
- Interventions
- First Posted Date
- 2020-11-19
- Last Posted Date
- 2024-08-02
- Lead Sponsor
- Astex Pharmaceuticals, Inc.
- Target Recruit Count
- 20
- Registration Number
- NCT04637009
- Locations
- 🇺🇸
University of Southern California Keck School of Medicine, Los Angeles, California, United States
🇺🇸Cleveland Clinic Taussig Cancer Institute, Cleveland, Ohio, United States
🇺🇸Augusta University - Georgia Cancer Center, Augusta, Georgia, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath